【摘要】：目的探討?zhàn)ひ罕砥影�、腺樣囊性癌和腺泡�?xì)胞癌中EGFR和HER-2基因/蛋白表達(dá)及臨床意義。方法采用免疫組化EnVision兩步法檢測(cè)80例涎腺癌(黏液表皮樣癌30例、腺樣囊性癌30例、腺泡細(xì)胞癌20例)和30例良性多形性腺瘤中EGFR和HER-2蛋白表達(dá);采用熒光原位雜交技術(shù)檢測(cè)涎腺癌中EGFR和HER-2基因擴(kuò)增。結(jié)果 (1)涎腺癌中EGFR和HER-2蛋白陽性率分別為71.25%和32.5%,高于良性多形性腺瘤組(P均0.05),其中以黏液表皮樣癌中EGFR和HER-2蛋白陽性率最高,EGFR蛋白的表達(dá)強(qiáng)度最高(P均0.05)。(2)EGFR和HER-2蛋白表達(dá)與涎腺癌患者性別、年齡、腫瘤最大直徑、腫瘤分化程度、組織學(xué)亞型無關(guān)(P均0.05);涎腺癌中EGFR和HER-2蛋白表達(dá)無相關(guān)性(rs=0.166,P0.05)。(3)涎腺癌中EGFR基因高多體擴(kuò)增的總陽性率為18.75%(15/80),其中黏液表皮樣癌13例,腺樣囊性癌2例,陽性率分別為43.3%和6.7%,相應(yīng)蛋白表達(dá)強(qiáng)度均為(嘌)或(嘁),表達(dá)強(qiáng)度和基因擴(kuò)增之間呈明顯正相關(guān)(rs=0.491,P0.01);涎腺癌中未檢測(cè)到HER-2基因擴(kuò)增及17號(hào)染色體多體。(4)EGFR蛋白(嘌/嘁)組和基因擴(kuò)增組患者的生存時(shí)間比蛋白(-/+)組和無基因擴(kuò)增組均明顯縮短(P均0.05)。結(jié)論黏液表皮樣癌高頻率、高強(qiáng)度表達(dá)EGFR,并發(fā)生高多體基因擴(kuò)增,可作為其分子靶向治療的靶點(diǎn)。黏液表皮樣癌、腺樣囊性癌和腺泡細(xì)胞癌中HER-2蛋白弱表達(dá),未檢測(cè)到基因擴(kuò)增。
[Abstract]:Objective to investigate the expression and clinical significance of EGFR and HER-2 gene / protein in mucoepidermoid carcinoma, adenoid cystic carcinoma and acinar cell carcinoma. Methods the expression of EGFR and HER-2 protein in 80 cases of salivary gland carcinoma (30 cases of mucoepidermoid carcinoma, 30 cases of adenoid cystic carcinoma, 20 cases of acinar cell carcinoma) and 30 cases of benign pleomorphic adenoma were detected by immunohistochemical EnVision two-step method. The amplification of EGFR and HER-2 genes in salivary gland carcinoma was detected by fluorescence in situ hybridization. Results (1) the positive rates of EGFR and HER-2 protein in salivary gland carcinoma were 71.25% and 32.5%, respectively, which were higher than those in benign pleomorphic adenoma group (P 0.05). The highest positive rate of EGFR and HER-2 protein in mucoepidermoid carcinoma was found in mucoepidermoid carcinoma (P 0.05). (2). Protein expression and sex in patients with salivary gland carcinoma, There was no correlation between EGFR and HER-2 protein expression (rs=0.166,P0.05). (3) in salivary gland carcinoma (rs=0.166,P0.05). (3). The total positive rate of high multibody amplification of EGFR gene in salivary gland carcinoma was 18.75% (15 / 80), including 13 cases of mucoepidermoid carcinoma. 2 cases of adenoid cystic carcinoma, The positive rates were 43. 3% and 6. 7%, respectively. The corresponding protein expression intensity was either puor or scratch, and there was a positive correlation between the expression intensity and gene amplification (rs=0.491,P0.01), no amplification of HER-2 gene and polyploid of chromosome 17 were detected in salivary gland carcinoma. (4) EGFR protein. The survival time of the patients in the scratch group and the gene amplification group was significantly shorter than that in the protein (- /) group and the non-gene amplification group (P 0.05). Conclusion the mucoepidermoid carcinoma has high frequency and high intensity of EGFR, expression and high polymorphic gene amplification. It can be used as a target for molecular targeting therapy of mucoepidermoid carcinoma. HER-2 protein was weakly expressed in mucoepidermoid carcinoma, adenoid cystic carcinoma and acinar cell carcinoma.
【作者單位】： 江蘇省連云港市第一人民醫(yī)院病理科;江蘇省連云港市第一人民醫(yī)口腔科;
【基金】：連云港市衛(wèi)生局課題(1206)
【分類號(hào)】：R739.87

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 Jill Wykosky;Tim Fenton;Frank Furnari;Webster K. Cavenee;;Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations[J];癌癥;2011年01期

2 章建國(guó);陸錦標(biāo);施公勝;張弘;;解聚素金屬蛋白酶和表皮生長(zhǎng)因子受體在涎腺腺樣囊性癌中的表達(dá)及臨床意義[J];交通醫(yī)學(xué);2012年01期

3 劉媛;邵樂南;陳衛(wèi)民;何偉;王琳琳;;EGFR和C-erbB-2在涎腺腫瘤中的表達(dá)及其意義[J];臨床口腔醫(yī)學(xué)雜志;2008年05期

4 陳晶晶;陳柯;王曉秋;;子宮內(nèi)膜癌組織中Id-1、VEGF-C和EGFR的表達(dá)及臨床意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2010年02期

5 宋國(guó)新;李紅芬;李霄;張煒明;;熒光原位雜交與免疫組織化學(xué)檢測(cè)胃癌組織中HER-2基因及蛋白表達(dá)一致性[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2012年10期

6 周曉秋;王東關(guān);孫希印;高虹;王琳琳;李新功;;非小細(xì)胞肺癌EGFR基因和蛋白檢測(cè)的比較分析[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2012年10期

7 洪蔭;涂健;朱旬;馮一中;鄒漢青;朱培培;楊汶士;王亮;王國(guó)強(qiáng);;乳腺癌組織中E-cad表達(dá)與EGFR、HER-2表達(dá)的關(guān)系[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2013年11期

8 Chao He;Xue-Yi Bian;Xing-Zhi Ni;Dan-Ping Shen;Yan-Ying Shen;Hua Liu;Zhi-Yong Shen;Qiang Liu;;Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer[J];World Journal of Gastroenterology;2013年14期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Olli Yli-Harja;Antti Ylip釨釨;Matti Nykter;;Cancer systems biology:signal processing for cancer research[J];癌癥;2011年04期

2 焦昕;金波;曲秀娟;閆順朝;侯科佐;劉云鵬;胡雪君;;c-Cbl、Cbl-b和EGFR在非小細(xì)胞肺癌中的表達(dá)及其預(yù)后價(jià)值[J];中國(guó)肺癌雜志;2011年06期

3 German G.Gomez;Jill Wykosky;Ciro Zanca;Frank B.Furnari;Webster K.Cavenee;;Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks[J];Cancer Biology & Medicine;2013年04期

4 陳昊;王紅霞;閆蓉;張春芳;劉毅;徐宏志;;3種惡性涎腺上皮性腫瘤EGFR和HER-2表達(dá)的差異及意義[J];廣東醫(yī)學(xué);2013年21期

5 曹新梅;張岱權(quán);王栩;夏紀(jì)毅;黃黎;高燕;;C-erbB-2 shRNA對(duì)小鼠肺腺癌細(xì)胞化療敏感性的影響及其機(jī)制[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年04期

6 Li Yan;;Molecular targeted agents—where we are and where we are going[J];Chinese Journal of Cancer;2013年05期

7 邱建龍;楊維群;徐海剛;;Id2在上皮性卵巢腫瘤中的表達(dá)及意義[J];臨床腫瘤學(xué)雜志;2011年12期

8 于曉紅;葉璐;丁洪慧;舒寬勇;魏寶秀;;卵巢黏液性腫瘤中EGFR表達(dá)和K-RAS基因的突變[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2011年08期

9 于雪梅;李新軍;吳戈;付明霞;張建;趙松林;;胃癌組織中HER-2基因擴(kuò)增和蛋白的表達(dá)[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2013年10期

10 李洋;朱穎軍;石巖蓉;林琬君;;EGF和TGF-a在子宮內(nèi)膜癌中的表達(dá)[J];實(shí)用臨床醫(yī)學(xué);2014年03期

相關(guān)博士學(xué)位論文 前3條

1 駱海明;用于鼻咽癌高效靶向診療的多肽—脂質(zhì)納米探針的研制[D];華中科技大學(xué);2013年

2 駱海明;用于鼻咽癌高效靶向診療的多肽—脂質(zhì)納米探針的研制[D];華中科技大學(xué);2013年

3 侯雯e，

本文編號(hào)：2202255